文献速递消化道肿瘤与早癌胃肠动力与功能性疾病

肠道拟杆菌通过色氨酸代谢物介导伊立替康毒性敏感性

Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites.
PubMed 文献 · Gut · 2026-06-09

该研究探讨了肠道细菌代谢物在伊立替康毒性易感性中的作用。通过分析结直肠癌患者肠道菌群与代谢物,并结合小鼠实验,发现Bacteroides intestinalis通过产生色氨酸代谢物IAA抑制PI3K-Akt信号,加剧伊立替康诱导的肠上皮损伤,且粪便IAA水平与腹泻严重程度相关。

要点

  • Bacteroides intestinalis在伊立替康腹泻易感患者及小鼠中显著扩增。
  • IAA通过抑制PI3K-Akt信号损害伊立替康损伤下的肠上皮更新。
  • 粪便IAA水平与接受伊立替康治疗患者的腹泻严重程度密切相关。

核心结论

  • 肠道细菌代谢物IAA塑造了伊立替康毒性的个体易感性,并可作为潜在预测生物标志物。

研究设计与样本

  • 通过16S rRNA测序、鸟枪法宏基因组学和代谢组学分析结直肠癌患者肠道菌群与代谢物。
  • 利用代谢生物工程和肠道类器官培养在小鼠中研究微生物代谢物的作用。
  • 通过转录谱分析和化学干预研究微生物代谢物对肠道干细胞的机制。

主要发现

  • 伊立替康治疗腹泻与非腹泻患者的肠道微生物构型存在差异重塑,且易感性可通过基线粪便微生物移植传递给小鼠。
  • Bacteroides intestinalis在腹泻易感队列及伊立替康治疗小鼠中显著扩增。
  • B. intestinalis定植部分通过色氨酸代谢物IAA使肠上皮对伊立替康诱导的化学损伤敏感。
  • 产IAA的B. intestinalis和生物工程菌均加剧小鼠伊立替康诱导的肠上皮损伤。
  • IAA抑制PI3K-Akt信号,从而损害伊立替康损伤下肠上皮的更新。

关键数值与推荐

  • 在接受伊立替康治疗的临床患者中,粪便IAA水平与腹泻严重程度密切相关。

临床怎么用

  • 粪便IAA水平可能作为预测伊立替康腹泻易感性的生物标志物。
  • 靶向B. intestinalis或IAA通路或可减轻伊立替康肠道毒性。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Late-onset diarrhoea remains a poorly managed concern for clinical irinotecan therapy. Although bacterial β-glucuronidases (β-GUS) mediated SN-38 production is prevailingly thought to mediate intestinal toxicity, β-GUS inhibitors confer limited benefits in the clinic. OBJECTIVE: This study aimed to explore the role and mechanism of endogenous bacterial metabolites in susceptibility to irinotecan toxicity. DESIGN: Gut microbiota profiles and metabolites in patients with colorectal cancer (CRC) with or without diarrhoea were investigated via 16S rRNA sequencing, shotgun metagenomics and metabolomics. The role of microbial metabolites was investigated in mice by metabolic bioengineering and intestinal organoid culture. The mechanism of microbial metabolites on intestinal stem cells was investigated by transcriptional profiling and chemical intervention. RESULTS: Gut microbial configuration was differentially remodelled in diarrhoea and non-diarrhoea patients with irinotecan therapy, and the susceptibility was transmissible to recipient mice via transplantation of baseline faecal microbiome. Bacteroides intestinalis (B. intestinalis) was notably expanded in the diarrhoea-prone cohorts as well as in irinotecan-treated mice. B. intestinalis colonisation sensitised intestinal epithelia to irinotecan-induced chemical injury, partially via tryptophan metabolite indole-3-acetate (IAA). Both B. intestinalis and bioengineered bacteria that produce IAA exacerbated irinotecan-induced intestinal epithelial injury in mice. Mechanistically, IAA suppressed PI3K-Akt signalling, thereby impairing the renewal of intestinal epithelia under the insult of irinotecan. In clinical patients receiving irinotecan therapy, faecal IAA level was closely associated with the diarrhoea severity. CONCLUSION: Our study uncovers the mechanism of endogenous bacterial metabolite in shaping the individual susceptibility to irinotecan toxicity and suggests IAA as a potential predictive biomarker.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Hou Y, Wu H, Zhang Z, et al. Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites. Gut. 2026. PMID: 40903035. doi:10.1136/gutjnl-2024-334699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。